<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1972">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081208</url>
  </required_header>
  <id_info>
    <org_study_id>16-OBE001-005</org_study_id>
    <nct_id>NCT03081208</nct_id>
  </id_info>
  <brief_title>Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI</brief_title>
  <acronym>IMPLANT2</acronym>
  <official_title>A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Oral Administration of Nolasiban to Improve Pregnancy Rates Following IVF or ICSI in Day 3 and Day 5 Fresh Embryo Transfer Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to confirm the efficacy of a single oral 900mg dose
      of nolasiban to increase the ongoing clinical pregnancy rate at 10 weeks post embryo
      transfer (ET) day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, parallel group, double-blind, placebo-controlled
      study to confirm the efficacy and the safety of the oxytocin receptor antagonist, nolasiban,
      in 760 women undergoing fresh embryo transfer following in vitro fertilisation (IVF) or
      intra-cytoplasmic sperm injection (ICSI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-uterine pregnancy with fetal heart beat at 10 weeks</measure>
    <time_frame>10 weeks post ET day</time_frame>
    <description>Intra-uterine pregnancy with fetal heart beat at 10 weeks post embryo transfer day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth</measure>
    <time_frame>Up to 42 weeks of gestation</time_frame>
    <description>Live birth after 24 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>From 6 weeks post ET to 24 weeks gestation</time_frame>
    <description>Any clinical pregnancy that does not result in a live birth prior 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-uterine pregnancy at 6 weeks</measure>
    <time_frame>6 weeks post ET</time_frame>
    <description>Intra-uterine pregnancy with fetal heart beat at 6 weeks post ET day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive blood pregnancy test</measure>
    <time_frame>14 days post OPU</time_frame>
    <description>Positive blood pregnancy test at 14 days post oocyte pick-up (OPU)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, up to 11 months</time_frame>
    <description>Frequency and severity of treatment emergent adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal assessments</measure>
    <time_frame>Birth of infant until 28 days</time_frame>
    <description>Incidence of any malformation or any significant morbidity during the neonatal period</description>
  </other_outcome>
  <other_outcome>
    <measure>ASQ-3</measure>
    <time_frame>6 months after term</time_frame>
    <description>Ages and Stages Questionnaire-3 (ASQ-3) domain score(s) at 6 months, adjusted for gestational age at birth</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Nolasiban 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nolasiban 900mg</intervention_name>
    <description>Nolasiban dispersible tablets for single oral administration</description>
    <arm_group_label>Nolasiban 900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dispersible tablets for single oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Indicated for IVF/ICSI in the context of assisted reproductive technology (ART)

          -  Follow a gonadotropin releasing hormone (GnRH) antagonist protocol, single injection
             of human chorionic gonadotropin (hCG) for triggering final follicular maturation and
             luteal phase support with vaginal micronized progesterone.

          -  Single, fresh D3 or D5 embryo transfer

        Key Exclusion Criteria:

          -  Frozen-thawed embryo transfer

          -  More than 20 oocytes in the current controlled ovarian hyperstimulation (COH) cycle

          -  Serum P4 greater than 1.5 ng/mL on the day of hCG administration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ObsEva SA</last_name>
    <role>Study Director</role>
    <affiliation>Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>+41225523840</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belgium</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
